UCSF |
|
CRISPR Therapeutics |
B Cell Malignancies Non-hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL |
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies |
No longer active |
|
UCSF |
|
Cellectis, SA |
Multiple Myeloma |
Phase I, open label dose‐escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T‐cells expressing anti‐CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Mu |
No longer active |
|
UCSF |
|
Poseida Therapeutics, Inc. |
Prostate cancer |
A Phase 1 Dose Escalation and Expanded Cohort Study of P‑PSMA‑101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) |
No longer active |
|
UCSF |
|
Allo Vir, Inc. |
BK Viremia in Kidney Transplant Recipients |
Phase 2 study in patients with BK Viremia in Kidney Transplant Recipients |
No longer active |
|
UCSF |
|
Talaris |
Transplanted Organ Rejection |
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1) |
No longer active |
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas |
Active, not recruiting |
|
City of Hope |
|
City of Hope |
Cancer - Lymphoma (AIDS-Related) |
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma |
Active, not recruiting |
|
City of Hope |
|
Adaptimmune |
Cancer - Lung |
A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
|
City of Hope |
|
Adaptimmune |
Cancer - Sarcoma |
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma |
Active, not recruiting |
|
City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) |
Active, not recruiting |
|
UCLA |
|
Orchard Therapeutics |
Severe Combined Immunodeficiency (SCID) |
Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency |
Active, not recruiting |
|
UCLA |
|
UCLA |
Severe Combined Immunodeficiency (SCID) |
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) |
Active, not recruiting |
|
UCLA |
|
UCLA |
X-linked Chronic Granulomatous Disease |
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease |
Active, not recruiting |
|
UCSD & City of Hope |
|
UCSD |
Cancer - Leukemia |
A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
Active, not recruiting |
|
UCSD |
|
UCSD |
Cancer - Breast |
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer |
Active, not recruiting |
|
UCLA |
|
UCLA |
Cancer - Lung |
A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
Active, not recruiting |
|
UCI |
|
Longeveron |
Aging frailty |
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty |
Active, not recruiting |
|
UCI & UCSD & UC Davis |
|
Aivita Biomedical |
Cancer - Brain |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma |
Active, not recruiting |
|
UCI & UC Davis |
|
Humacyte |
Kidney failure |
A Phase 3 Study to Compare the Efficacy and Safety of Humacyte’s Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease |
Active, not recruiting |
|
City of Hope |
|
City of Hope |
Cancer - Lymphoma |
Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) |
Active, not recruiting |
|
UC Davis |
|
UC Davis |
B-Cell Leukemia |
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies |
Active, not recruiting |
|
UCI |
|
Brain Neurotherapy Bio |
Parkinson's |
Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson’s Disease |
Active, not recruiting |
|
UCI & UC Davis |
|
Celularity, Inc. |
Hospitalized COVID-19 patients |
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 |
Active, not recruiting |
|
UCSD |
|
Aivita |
Ovarian and Fallopian Tube Carcinoma |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas |
Active, not recruiting |
|
UCSD |
|
UCSD/Oncternal |
chronic lymphocytic leukemia |
Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax |
Active, not recruiting |
|
UCSD |
|
Tigenix |
Crohn's Disease |
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn’s Disease (CD) |
Active, not recruiting |
|
UC Davis |
|
Autolus |
Acute Lymphoblastic Leukaemia |
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia |
Active, not recruiting |
|
UCSF |
|
Passage Bio Inc. |
GM1 Gangliosidosis |
A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subjects Aged 4 to 24 Months with Type 1 (Early Onset Infant |
Active, not recruiting |
|
UCSF |
|
CIRM & NHLBI |
Severe sickle cell disease |
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease |
Active, not recruiting |
|